Switch theme
Sign up to access all valuation multiples
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
2006
14
LTM Revenue $0.5M
LTM EBITDA -$62.7M
-$30.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sagimet Biosciences has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of -$62.7M.
In the most recent fiscal year, Sagimet Biosciences achieved revenue of n/a and an EBITDA of -$54.5M.
Sagimet Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sagimet Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$62.7M | XXX | -$54.5M | XXX | XXX | XXX |
| EBITDA Margin | -12125% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$69.3M | XXX | -$54.5M | XXX | XXX | XXX |
| EBIT Margin | -13404% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$61.0M | XXX | -$45.6M | XXX | XXX | XXX |
| Net Margin | -11805% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sagimet Biosciences's stock price is $4.
Sagimet Biosciences has current market cap of $114M, and EV of -$30.2M.
See Sagimet Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$30.2M | $114M | XXX | XXX | XXX | XXX | $-1.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sagimet Biosciences has market cap of $114M and EV of -$30.2M.
Sagimet Biosciences's trades at -15.1x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Sagimet Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sagimet Biosciences has a P/E ratio of -1.9x.
See valuation multiples for Sagimet Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV (current) | -$30.2M | XXX | -$30.2M | XXX | XXX | XXX |
| EV/Revenue | -58.5x | XXX | -15.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.6x | XXX | XXX | XXX |
| EV/Gross Profit | -58.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -2.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSagimet Biosciences's last 12 month revenue growth is 42%
Sagimet Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.9M for the same period.
Sagimet Biosciences's rule of 40 is -1495% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sagimet Biosciences's rule of X is -12019% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sagimet Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -12125% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | 56% | XXX | XXX | XXX |
| Rule of 40 | -1495% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -12019% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sagimet Biosciences acquired XXX companies to date.
Last acquisition by Sagimet Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Sagimet Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sagimet Biosciences founded? | Sagimet Biosciences was founded in 2006. |
| Where is Sagimet Biosciences headquartered? | Sagimet Biosciences is headquartered in United States of America. |
| How many employees does Sagimet Biosciences have? | As of today, Sagimet Biosciences has 14 employees. |
| Who is the CEO of Sagimet Biosciences? | Sagimet Biosciences's CEO is Mr. David Happel. |
| Is Sagimet Biosciences publicy listed? | Yes, Sagimet Biosciences is a public company listed on NAS. |
| What is the stock symbol of Sagimet Biosciences? | Sagimet Biosciences trades under SGMT ticker. |
| When did Sagimet Biosciences go public? | Sagimet Biosciences went public in 2023. |
| Who are competitors of Sagimet Biosciences? | Similar companies to Sagimet Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sagimet Biosciences? | Sagimet Biosciences's current market cap is $114M |
| What is the current revenue of Sagimet Biosciences? | Sagimet Biosciences's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Sagimet Biosciences? | Sagimet Biosciences revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Sagimet Biosciences? | Current revenue multiple of Sagimet Biosciences is -58.5x. |
| Is Sagimet Biosciences profitable? | Yes, Sagimet Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sagimet Biosciences? | Sagimet Biosciences's last 12 months EBITDA is -$62.7M. |
| What is Sagimet Biosciences's EBITDA margin? | Sagimet Biosciences's last 12 months EBITDA margin is -12125%. |
| What is the current EV/EBITDA multiple of Sagimet Biosciences? | Current EBITDA multiple of Sagimet Biosciences is 0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
